<- Go Home
CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.
Market Cap
$3.7B
Volume
1.9M
Cash and Equivalents
$206.5M
EBITDA
-$101.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$49.7M
Profit Margin
-160.03%
52 Week High
$32.50
52 Week Low
$7.26
Dividend
N/A
Price / Book Value
12.65
Price / Earnings
-32.74
Price / Tangible Book Value
12.65
Enterprise Value
$3.4B
Enterprise Value / EBITDA
-34.17
Operating Income
-$101.7M
Return on Equity
-64.17%
Return on Assets
-22.05
Cash and Short Term Investments
$394.3M
Debt
$114.5M
Equity
$292.3M
Revenue
$31.1M
Unlevered FCF
-$43.0M
Sector
Pharmaceuticals
Category
N/A